%0 Journal Article
%T The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner
%A Barry Trink
%A Giacomo Basadonna
%A Jerome Canady
%A Lawan Ly
%A Michael Keidar
%A Taisen Zhuang
%A Warren Rowe
%A Xiaoqian Cheng
%J -
%D 2018
%R https://doi.org/10.3390/plasma1010016
%X Abstract To determine appropriate treatment doses of cold atmospheric plasma (CAP), the Canady Helios Cold Plasma Scalpel was tested across numerous cancer cell types including renal adenocarcinoma, colorectal carcinoma, pancreatic adenocarcinoma, ovarian adenocarcinoma, and esophageal adenocarcinoma. Various CAP doses were tested consisting of both high (3 L/min) and low (1 L/min) helium flow rates, several power settings, and a range of treatment times up to 5 min. The impact of cold plasma on the reduction of viability was consistently dose-dependent; however, the anti-cancer capability varied significantly between cell lines. While the lowest effective dose varied from cell line to cell line, in each case an 80¨C99% reduction in viability was achievable 48 h after CAP treatment. Therefore, it is critical to select the appropriate CAP dose necessary for treating a specific cancer cell type. View Full-Tex
%K cold atmospheric plasma
%K CAP
%K cancer therapy
%K dose-dependent
%K renal adenocarcinoma
%K colorectal carcinoma
%K pancreatic adenocarcinoma
%K ovarian adenocarcinoma
%K esophageal adenocarcinoma
%U https://www.mdpi.com/2571-6182/1/1/16